Protara Therapeutics
TARAPhase 3Protara Therapeutics is a publicly traded biotech focused on advancing novel therapies for rare diseases and cancer. Its pipeline leverages proprietary delivery platforms, including an intravesical delivery system for bladder cancer and an intravenous phospholipid substrate for IFALD. The company's strategy centers on addressing significant unmet medical needs in specialized therapeutic areas with high-value potential.
TARA · Stock Price
Historical price data
AI Company Overview
Protara Therapeutics is a publicly traded biotech focused on advancing novel therapies for rare diseases and cancer. Its pipeline leverages proprietary delivery platforms, including an intravesical delivery system for bladder cancer and an intravenous phospholipid substrate for IFALD. The company's strategy centers on addressing significant unmet medical needs in specialized therapeutic areas with high-value potential.
Technology Platform
Protara develops proprietary delivery platforms, including an intravesical system for localized immunotherapy in bladder cancer and an intravenous phospholipid substrate replacement for metabolic deficiencies.
Pipeline
6| Drug | Indication | Stage | Watch |
|---|---|---|---|
| TARA-002 + Investigator's Choice of Intravesical Chemotherap... | Bladder (Urothelial, Transitional Cell) Cancer | Phase 3 | |
| Choline Chloride for Injection + Placebo | Choline Deficiency | Phase 2/3 | |
| TARA-002 | Non-muscle Invasive Bladder Cancer | Phase 2 | |
| TARA-002 | Lymphatic Malformation | Phase 2 | |
| TARA-002 | Non-muscle Invasive Bladder Cancer | Phase 1 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
In bladder cancer, competes with approved gene therapy (Adstiladrin) and systemic immunotherapies, as well as other late-stage investigational agents. In IFALD, faces competition from surgical intervention (transplant) but has no direct pharmacologic competitors, offering a unique market position.